Table 2.
Association of different clinical and pathological characteristics with neutrophil-to-lymphocyte ratio in patients with nonmetastatic renal cell carcinoma.
| Variable | All | Low NLR | High NLR | p value |
|---|---|---|---|---|
| Number of subjects | 1,284 | 1,168 | 116 | |
| NLR, mean ± SD | 2.2 ± 1.7 | 1.8 ± 0.7 | 6.0 ± 3.2 | <0.001∗ |
| Age, mean ± SD, year | 55.9 ± 12.9 | 55.5 ± 12.8 | 59.8 ± 12.9 | 0.001∗ |
| Gender | 0.236∗∗ | |||
| Male, n (%) | 913 (71.1) | 825 (70.6) | 88 (75.9) | |
| Female, n (%) | 371 (28.9) | 343 (29.4) | 28 (24.1) | |
| BMI, mean ± SD, kg/m2 | 24.6 ± 3.3 | 24.7 ± 3.2 | 23.8 ± 3.4 | 0.006∗ |
| ECOG PS ≥ 1, n (%) | 180 (14.0) | 148 (12.7) | 32 (27.6) | <0.001∗∗ |
| Symptoms at presentation | 0.003∗∗ | |||
| No symptom, n (%) | 975 (75.9) | 900 (77.1) | 75 (64.7) | |
| Symptom, n (%) | 309 (24.1) | 268 (22.9) | 41 (35.3) | |
| Tumor size | ||||
| (1) mean ± SD, cm | 4.08 ± 2.68 | 3.94 ± 2.54 | 5.50 ± 3.55 | <0.001∗ |
| (2) Category | <0.001∗∗ | |||
| <4 cm, n (%) | 748 (58.3) | 701 (60.0) | 47 (40.5) | |
| 4–7 cm, n (%) | 351 (27.3) | 321 (27.5) | 30 (25.9) | |
| ≥7 cm, n (%) | 185 (14.4) | 146 (12.5) | 39 (33.6) | |
| Side | 1.000∗∗∗ | |||
| Unilateral, n (%) | 1,268 (98.8) | 1,153 (98.7) | 115 (99.1) | |
| Bilateral, n (%) | 16 (1.2) | 15 (1.3) | 1 (0.9) | |
| Type of nephrectomy | <0.001∗∗ | |||
| Radical, n (%) | 634 (49.4) | 552 (47.3) | 82 (70.7) | |
| Partial, n (%) | 650 (50.6) | 616 (52.7) | 34 (29.3) | |
| Method of surgery | 0.042∗∗ | |||
| Open, n (%) | 697 (54.3) | 628 (53.8) | 69 (59.5) | |
| Laparoscopic, n (%) | 316 (24.6) | 283 (24.2) | 33 (28.4) | |
| Robot, n (%) | 271 (21.1) | 257 (22.0) | 14 (12.1) | |
| T stage | <0.001∗∗ | |||
| T1, n (%) | 1,016 (79.1) | 945 (80.9) | 71 (61.2) | |
| T2, n (%) | 89 (6.9) | 75 (6.4) | 14 (12.1) | |
| T3-4, n (%) | 179 (13.9) | 148 (12.7) | 31 (26.7) | |
| Fuhrman's grade | 0.561∗∗ | |||
| G1-2, n (%) | 664 (51.7) | 607 (52.0) | 57 (49.1) | |
| G3-4, n (%) | 620 (48.3) | 561 (48.0) | 59 (50.9) | |
| Histologic subtype | 0.042∗∗ | |||
| Clear cell, n (%) | 1,114 (86.8) | 1,017 (87.1) | 97 (83.6) | |
| Papillary, n (%) | 87 (6.8) | 73 (6.3) | 14 (12.1) | |
| Chromophobe, n (%) | 83 (6.5) | 78 (6.7) | 5 (4.3) | |
| Sarcomatoid differentiation, yes, n (%) | 29 (2.3) | 22 (1.9) | 7 (6.0) | 0.004∗∗ |
| Tumor necrosis, yes, n (%) | 208 (16.2) | 174 (14.9) | 34 (29.3) | <0.001∗∗ |
| Recurrence, n (%) | 142 (11.1) | 114 (9.8) | 28 (24.1) | <0.001∗∗ |
| RCC-specific death, n (%) | 56 (4.4) | 40 (3.4) | 16 (13.8) | <0.001∗∗ |
NLR, neutrophil-to-lymphocyte ratio; low NLR, <3.7; high NLR, ≥3.7; BMI, body mass index; ECOG PS, Eastern Cooperative Oncology Group performance status; RCC, renal cell carcinoma; n, number of subjects; SD, standard deviation.
∗Student t-test.
∗∗Pearson's chi-square test.
∗∗∗Fisher's exact test.